CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback